Clinical Trials
30
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)β’ Click on a phase to view related trials
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
- Conditions
- Cocaine UseCocaine IntoxicationCocaine AbuseCocaine Adverse ReactionCocaine Toxicity
- Interventions
- Drug: TNX-1300 (Injection)Drug: Placebo (Injection)
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT06045793
- Locations
- πΊπΈ
University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
πΊπΈUniversity Of Maryland Medical Center, Baltimore, Maryland, United States
πΊπΈHenry Ford Health System, Detroit, Michigan, United States
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, MajorDepressive EpisodeDepression SevereDepressionDepressive DisorderDepressive Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT05686408
- Locations
- πΊπΈ
Cenexel Research - Decatur, Decatur, Georgia, United States
πΊπΈPreferred Research Partners, Little Rock, Arkansas, United States
πΊπΈCenexel CIT - Bellflower, Bellflower, California, United States
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
- Conditions
- Chronic MigraineChronic Migraine, HeadacheChronic Migraine Without AuraAura Migraine
- Interventions
- Drug: Placebo Nasal Spray
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT05679908
- Locations
- πΊπΈ
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
πΊπΈSynergy Research Centers - Synergy San Diego, Lemon Grove, California, United States
πΊπΈExcell Research, Oceanside, California, United States
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) InfectionCOVID-19Long COVIDLong Haul COVID
- Interventions
- Drug: Placebo SL Tablet
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05472090
- Locations
- πΊπΈ
Accel Research-Birmingham Clinical Research Unit, Birmingham, Alabama, United States
πΊπΈTonix Clinical Site, McKinney, Texas, United States
Safety and Efficacy Study of TNX-102 SL in Participants With PTSD
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Registration Number
- NCT05372887
- Locations
- π°πͺ
Aga Khan University Clinical Research Unit, Nairobi, Kenya
π°πͺCentre for Clinical Research at KEMRI-Nairobi, Nairobi, Kenya
π°πͺMoi University Clinical Research Centre, Nairobi, Kenya
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next